ÂÜÀòÂÒÂ×

Mr. Moshkevich is passionate about improving patient outcomes and lowering healthcare costs through non-invasive technologies and innovative reimbursement models. He began his career in New York as a consultant with Bain & Company, and then moved to Moscow, Russia in 2007 to lead a regional growth strategy for SABMiller. Returning to Boston, he joined the investment team at Parthenon Capital Partners where he invested in healthcare and business services companies. Later with the Disease Management team of OptumHealth (a UnitedHealth Group company), he was the first to identify and measure the value of provider engagement in Optum’s disease management services, which led to lower costs and improved patient outcomes. More recently, as a member of the start-up team at Organ-I, he developed a commercialization strategy for a non-invasive genetic test that detects the acute rejection of solid organ transplants. Since joining Natera in 2011, he has been responsible for launching Natera’s brands in more than 40 countries worldwide, and developing key channel partnerships in the United States. Mr. Moshkevich graduated summa cum laude from Columbia University with a B.A. in Economics and Mathematics and has an M.B.A. from Stanford University.